Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation.

The oncologist - 5 Aug 2024

Moore Casey, Naraine Isabel, Zhang Tian

Abstract excerpt

Prostate cancer is one of the most prevalent malignancies in men. In the United States, 1 in 8 men will be diagnosed with prostate cancer in their lifetime. Specifically, studies have delved into male subgroups that present a heightened risk for prostate cancer. Despite such high prevalence, prostate cancer can be heterogeneous and carry complexities that manifest differently between individuals. Metastatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antibodies, Monoclonal, Humanized
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 gene

Share to Microsatellite Instability

Share to Mutation

Share to Prostatic Neoplasms, Castration-Resistant

Share to Remission Induction

Source

Open in PubMed Open full text

Identifiers

PMID: 38920278
DOI: 10.1093/oncolo/oyae156
PMCID: PMC11299937

Genes

BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation.PMID 38920278Read ↗

Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic FrontiersSemantic proximity Read ↗

Molecular landscape of prostate cancer: Implications for current clinical trialsSemantic proximity Read ↗

The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

De Novo Metastatic Prostate Cancer: Are We Moving towards a Personalized Treatment?Semantic proximity Read ↗

[Molecular diagnostics and molecular tumor board in uro-oncology : Precision medicine using the example of metastatic castration-resistant prostate cancer].Semantic proximity Read ↗

An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKTSemantic proximity Read ↗

A Real-World Experience of Pembrolizumab Monotherapy in Microsatellite Instability-High and/or Tumor Mutation Burden-High Metastatic Castration-Resistant Prostate Cancer: Outcome AnalysisSemantic proximity Read ↗

Additive Clinical Utility of Microsatellite Instability and Tumor Mutational Burden to Predict Immune Checkpoint Inhibitor Effectiveness in Metastatic Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer.Semantic proximity Read ↗

Clinical phenotypes of castration-resistant prostate cancer.Semantic proximity Read ↗

Characteristics of BRCA2 Mutated Prostate Cancer at Presentation.Semantic proximity Read ↗

Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.